March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
On March 3, 2026, the FDA approved the first generic of Flovent HFA (fluticasone propionate) inhalation aerosol, 44 mcg per actuation, for the maintenance treatment of asthma as prophylactic therapy in...
A nationwide Belgian cohort study found that biologic therapy targeting interleukin (IL) 5 reduced moderate and severe exacerbations among adults with severe eosinophilic asthma, including those with...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, but it’s also highly manageable with early recognition, evidence-based treatment, and coordinated care. This guide...
In patients with severe asthma who experience persistent exacerbations despite biologic therapy, azithromycin reduced both steroid- and antibiotic-requiring events and improved symptom control, according to...
According to a post hoc analysis, in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, tezepelumab improved nasal and asthma symptoms across multiple...
The FDA has proposed new draft guidance to improve the accuracy of pulse oximeters across all skin tones, addressing long-standing concerns about potential disparities in performance.
A prospective study reveals that individuals with inflammatory bowel disease (IBD), ulcerative colitis, and Crohn disease have a significantly higher risk of developing chronic obstructive pulmonary disease...
In this video, Albert Rizzo, MD, speaks with allergist and immunologist Juanita Mora, MD, pediatrician John Harrington, MD, and pulmonary and critical care physician, David Hill, MD, about the role of a...
